Intelligent Bio Solutions Reports 38.1% Revenue Growth to $4.2 Million for Fiscal Year Ending June 30, 2026

Intelligent Bio Solutions Inc. (INBS) reported a significant increase in revenue for the fiscal year ending June 30, 2026, achieving $4.2 million, a 38.1% rise from $3.1 million in the previous year. This growth was primarily driven by a 41.1% increase in sales of cartridge consumables, which reflects the company's successful strategy to expand its customer base, adding 116 new customers during the year. Despite the revenue growth, the company reported a net loss of $12.4 million, up from a loss of $10.6 million in the prior year, attributed to increased operating expenses, particularly in marketing and regulatory approval efforts.

The company's operational focus has shifted towards enhancing its product offerings and expanding market reach. INBS has made strategic investments in marketing, resulting in a 33% increase in marketing expenses to $2.1 million. Additionally, the company has ramped up its research and development (R&D) efforts, with expenses rising to $3.4 million, as it prepares for a new FDA 510(k) submission for its Intelligent Fingerprinting Drug Screening System. This system, which utilizes fingerprint sweat for drug testing, is currently available in select international markets, and the company aims to broaden its capabilities to include additional drug tests.

In terms of operational metrics, INBS has established a solid foundation for future growth, with a gross profit margin improvement to 48.6%, up from 40.9% the previous year. This increase is attributed to enhanced operational efficiencies and a favorable sales mix. The company also reported a contribution margin of 73.4%, indicating effective management of direct costs associated with its products. As of June 30, 2026, INBS had cash and cash equivalents of approximately $4 million, but raised concerns about its ability to fund operations over the next twelve months without additional capital.

Strategically, INBS has been active in forming partnerships and expanding its distribution network. The company has entered into collaborations with various organizations, including a significant partnership with Bouygues UK for deploying its drug screening technology. Furthermore, INBS is exploring opportunities in the Asia-Pacific region and aims to establish a strategic network of distributors to enhance its market presence. The company is also navigating regulatory pathways to secure necessary approvals for its products, which is critical for its expansion plans.

Looking ahead, INBS acknowledges the challenges it faces, including the need for additional capital to sustain operations and the complexities of regulatory compliance. The company is committed to addressing these challenges while continuing to innovate and expand its product offerings in the medical technology sector. The management's outlook remains focused on leveraging its unique fingerprint-based testing technology to capture a larger share of the growing drug screening and point-of-care diagnostics markets.